BG63538B1 - Стабилна нехигроскопична кристална форма на n-[n-n-(4-пиперидин-4-ил) бутаноил)-n-етилглицил] съединения - Google Patents

Стабилна нехигроскопична кристална форма на n-[n-n-(4-пиперидин-4-ил) бутаноил)-n-етилглицил] съединения Download PDF

Info

Publication number
BG63538B1
BG63538B1 BG103225A BG10322599A BG63538B1 BG 63538 B1 BG63538 B1 BG 63538B1 BG 103225 A BG103225 A BG 103225A BG 10322599 A BG10322599 A BG 10322599A BG 63538 B1 BG63538 B1 BG 63538B1
Authority
BG
Bulgaria
Prior art keywords
compound
acid
cycloalkyl
alkyl
protecting group
Prior art date
Application number
BG103225A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103225A (en
Inventor
Zofia CHRZAN
James Mencel
David Toledo-Velasquez
Vincent Windisch
Rick WOODWARD
Diane SELAZAR
Narasimha VEMURI
Anthony GARDETTO
Matthew Powers
Gregory KUBIAK
Robert Liu
Benoit VANASSE
James SHERBINE
Walter Rodriguez
Adam SLEDESKI
Original Assignee
Aventis Pharmaceuticals Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Products Inc. filed Critical Aventis Pharmaceuticals Products Inc.
Publication of BG103225A publication Critical patent/BG103225A/xx
Publication of BG63538B1 publication Critical patent/BG63538B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BG103225A 1996-08-21 1999-03-04 Стабилна нехигроскопична кристална форма на n-[n-n-(4-пиперидин-4-ил) бутаноил)-n-етилглицил] съединения BG63538B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2428496P 1996-08-21 1996-08-21
PCT/US1997/014756 WO1998007696A1 (en) 1996-08-21 1997-08-21 Stable non-hygroscopic crystalline form of n-[n-n-(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl] compounds

Publications (2)

Publication Number Publication Date
BG103225A BG103225A (en) 2000-01-31
BG63538B1 true BG63538B1 (bg) 2002-04-30

Family

ID=21819807

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103225A BG63538B1 (bg) 1996-08-21 1999-03-04 Стабилна нехигроскопична кристална форма на n-[n-n-(4-пиперидин-4-ил) бутаноил)-n-етилглицил] съединения

Country Status (20)

Country Link
US (2) US6153588A (no)
EP (1) EP0923553B1 (no)
JP (1) JP4008499B2 (no)
KR (1) KR20000068229A (no)
CN (2) CN1491942A (no)
AP (1) AP9901462A0 (no)
AT (1) ATE390438T1 (no)
AU (1) AU733591B2 (no)
BG (1) BG63538B1 (no)
BR (1) BR9711340A (no)
CA (1) CA2263647C (no)
DE (1) DE69738601T2 (no)
EA (1) EA001362B1 (no)
IL (1) IL128561A0 (no)
NO (1) NO990721L (no)
OA (1) OA10979A (no)
PL (1) PL331772A1 (no)
SK (1) SK21999A3 (no)
WO (1) WO1998007696A1 (no)
ZA (1) ZA977510B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068229A (ko) * 1996-08-21 2000-11-25 오흘러 로스 제이. 안정한 비-흡습성의 결정성 형태의 ｎ-[ｎ-ｎ-(４-(피페리딘-４-일)부타노일)-ｎ-에틸글리실] 화합물
WO1999019294A1 (en) * 1997-05-14 1999-04-22 Aventis Pharmaceuticals Products Inc. Legal/Patents Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
AP1057A (en) * 1997-10-10 2002-04-08 Aventis Pharmaceuticals Products Inc Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides.
EP1155033A1 (en) * 1998-12-30 2001-11-21 Aventis Pharmaceuticals Products Inc. Process for preparing a stable non-hygroscopic crystalline n-[n-[n-(piperdin-4-yl)butanoyl)-n-ethylglycyl]-(l)-aspartyl]-ss-cyclohexylalanine amide
US20050238834A1 (en) * 2004-04-21 2005-10-27 Eastman Kodak Company High modulus label with compliant carrier sheet
WO2007024501A2 (en) 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US9704557B2 (en) * 2013-09-25 2017-07-11 Qualcomm Incorporated Method and apparatus for storing retention time profile information based on retention time and temperature
ES2924473T3 (es) 2015-12-21 2022-10-07 Univ Texas Tech System Sistema y procedimiento de síntesis de péptidos GAP en fase de solución
WO2019217116A1 (en) * 2018-05-06 2019-11-14 Gap Peptides Llc Method for solution-phase peptide synthesis
WO2020159837A1 (en) 2019-02-01 2020-08-06 Gap Peptides Llc Synthesis strategy for gap protecting group

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
US5264420A (en) 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
US5218138A (en) 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0706999A1 (en) * 1993-06-30 1996-04-17 Sumitomo Pharmaceuticals Company, Limited Novel dipiperidine derivative
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
UA44258C2 (uk) * 1993-10-15 2002-02-15 Рон-Пуленк Рорер Фармасьютікалз Інк. Антитромботичні азациклоалкілалканоілпептиди та псевдопептиди, фармацевтична композиція, що їх містить, спосіб профілактики або лікування тромбозу у ссавців (варіанти)
KR100323274B1 (ko) 1993-10-19 2002-12-16 스미또모 세이야꾸 가부시키가이샤 2,3-디아미노프로피온산유도체
KR20000068229A (ko) * 1996-08-21 2000-11-25 오흘러 로스 제이. 안정한 비-흡습성의 결정성 형태의 ｎ-[ｎ-ｎ-(４-(피페리딘-４-일)부타노일)-ｎ-에틸글리실] 화합물
AP1057A (en) * 1997-10-10 2002-04-08 Aventis Pharmaceuticals Products Inc Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides.

Also Published As

Publication number Publication date
US6153588A (en) 2000-11-28
JP4008499B2 (ja) 2007-11-14
EP0923553A4 (en) 1999-12-08
CA2263647A1 (en) 1998-02-26
US6753409B1 (en) 2004-06-22
AP9901462A0 (en) 1999-03-31
JP2000517305A (ja) 2000-12-26
AU733591B2 (en) 2001-05-17
WO1998007696A1 (en) 1998-02-26
CN1231659A (zh) 1999-10-13
ATE390438T1 (de) 2008-04-15
CA2263647C (en) 2011-02-15
KR20000068229A (ko) 2000-11-25
DE69738601T2 (de) 2009-04-30
EA001362B1 (ru) 2001-02-26
AU4156397A (en) 1998-03-06
EP0923553B1 (en) 2008-03-26
NO990721L (no) 1999-04-20
BG103225A (en) 2000-01-31
DE69738601D1 (de) 2008-05-08
EP0923553A1 (en) 1999-06-23
ZA977510B (en) 1998-05-21
NO990721D0 (no) 1999-02-16
CN1491942A (zh) 2004-04-28
OA10979A (en) 2001-11-01
SK21999A3 (en) 2000-02-14
EA199900217A1 (ru) 1999-08-26
IL128561A0 (en) 2000-01-31
BR9711340A (pt) 1999-08-17
PL331772A1 (en) 1999-08-02

Similar Documents

Publication Publication Date Title
BG63538B1 (bg) Стабилна нехигроскопична кристална форма на n-[n-n-(4-пиперидин-4-ил) бутаноил)-n-етилглицил] съединения
US4952562A (en) Anti-thrombotic peptides and pseudopeptides
AP904A (en) Antithrombotic Azacycloalkylalkanoyl peptides and pseudopeptides.
US5866685A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
MXPA99001772A (en) Stable non-hygroscopic crystalline form of n-[n-n-(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl]compounds
US6797700B2 (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
MXPA99001773A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
CZ55099A3 (cs) Antitrombotické azacykloalkylalkanoylové peptidy a pseudopeptidy
CZ55199A3 (cs) Stabilní, nehygroskopická krystalická forma N- [N-[N(4-piperidin-4-yl)butanoyl]-N-ethylgIycyl]ových derivátů
NZ299833A (en) Treating or preventing thrombosis using azacycloalkanol peptides and pseudopeptides